

# Sanjay Mehta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6083777/publications.pdf>

Version: 2024-02-01

86  
papers

5,290  
citations

109137

35  
h-index

82410

72  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4708  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of pulmonary hypertension associated with COPD: a systematic review. ERJ Open Research, 2022, 8, 00348-2021.	1.1	9
2	SPECT/CT versus planar imaging to determine treatment strategy for non-small-cell lung cancer: a cost-effectiveness analysis. Journal of Comparative Effectiveness Research, 2022, , .	0.6	3
3	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	1.3	2
4	Nuclear imaging in chronic thromboembolic pulmonary hypertension: increasingly central to diagnosis and management. Journal of Nuclear Cardiology, 2022, 29, 3401-3404.	1.4	1
5	Cardiopulmonary Monitoring of Patients with Pulmonary Hypertension and Right Ventricular Failure. , 2021, , 871-903.		0
6	Pulmonary vascular diseases. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 108-113.	0.2	0
7	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 707-717.	2.5	89
8	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. Chest, 2020, 158, 2270-2274.	0.4	12
9	Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. Canadian Journal of Cardiology, 2020, 36, 977-992.	0.8	29
10	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 214-225.	0.2	3
11	Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19. Diagnostics, 2020, 10, 1053.	1.3	13
12	Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 675-685.	0.3	11
13	Diagnosis of chronic thromboembolic pulmonary hypertension: A Canadian Thoracic Society clinical practice guideline update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 177-198.	0.2	13
14	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	0.9	8
15	Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine. Journal of Thoracic Disease, 2019, 11, 21-28.	0.6	18
16	Quantification of adherens junction disruption and contiguous paracellular protein leak in human lung endothelial cells under septic conditions. Microcirculation, 2019, 26, e12528.	1.0	5
17	The importance of patient perspectives in pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801919.	3.1	85
18	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	1.2	82

#	ARTICLE	IF	CITATIONS
19	Differential Mechanisms of Septic Human Pulmonary Microvascular Endothelial Cell Barrier Dysfunction Depending on the Presence of Neutrophils. <i>Frontiers in Immunology</i> , 2018, 9, 1743.	2.2	9
20	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. <i>PLoS ONE</i> , 2018, 13, e0193226.	1.1	33
21	Caspase-Dependent Septic Pulmonary Microvascular Endothelial Cell Barrier Dysfunction is Associated with Vascular Endothelial-Cadherin Disruption. <i>FASEB Journal</i> , 2018, 32, 35.8.	0.2	0
22	Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2017, 151, 106-118.	0.4	46
23	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. <i>European Heart Journal</i> , 2017, 38, 1147-1155.	1.0	65
24	The Balance Between Metalloproteinases and TIMPs. <i>Progress in Molecular Biology and Translational Science</i> , 2017, 147, 101-131.	0.9	35
25	Inhibition of Murine Pulmonary Microvascular Endothelial Cell Apoptosis Promotes Recovery of Barrier Function under Septic Conditions. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	1.4	18
26	Changing face of pulmonary arterial hypertension in Canada. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 242-252.	0.2	5
27	Tissue inhibitor of metalloproteinases 3-dependent microvascular endothelial cell barrier function is disrupted under septic conditions. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H1455-H1467.	1.5	25
28	Pulmonary hypertension: the importance of correctly diagnosing the cause. <i>European Respiratory Review</i> , 2016, 25, 372-380.	3.0	9
29	Pulmonary hypertension: diagnostic approach and optimal management. <i>Cmaj</i> , 2016, 188, 804-812.	0.9	17
30	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. <i>European Respiratory Journal</i> , 2015, 46, 1711-1720.	3.1	39
31	Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo. <i>Respiratory Research</i> , 2015, 16, 109.	1.4	137
32	Early Decline in Six-Minute Walk Distance from the Time of Diagnosis Predicts Clinical Worsening in Pulmonary Arterial Hypertension. <i>Respiration</i> , 2015, 89, 365-373.	1.2	9
33	Effect of Macitentan on Hospitalizations. <i>JACC: Heart Failure</i> , 2015, 3, 1-8.	1.9	51
34	Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?. <i>European Respiratory Review</i> , 2014, 23, 458-468.	3.0	12
35	Apolipoprotein E-Deficient Mice Are Susceptible to the Development of Acute Lung Injury. <i>Respiration</i> , 2014, 87, 416-427.	1.2	29
36	Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1233-1240.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Pulmonary Microvascular Albumin Leak Is Associated with Endothelial Cell Death in Murine Sepsis-Induced Lung Injury In Vivo. PLoS ONE, 2014, 9, e88501.	1.1	66
38	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	13.9	1,168
39	Treatment Goals of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D73-D81.	1.2	250
40	Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. Journal of Cystic Fibrosis, 2013, 12, 817-820.	0.3	46
41	Human Alveolar Epithelial Cells Attenuate Pulmonary Microvascular Endothelial Cell Permeability under Septic Conditions. PLoS ONE, 2013, 8, e55311.	1.1	37
42	Specific Role of Neutrophil Inducible Nitric Oxide Synthase in Murine Sepsis-Induced Lung Injury In Vivo. Shock, 2012, 37, 539-547.	1.0	49
43	Treatment of Pulmonary Arterial Hypertension: Great Expectations!. Journal of Rheumatology, 2011, 38, 403-405.	1.0	1
44	Diagnostic Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Practice Guideline. Canadian Respiratory Journal, 2010, 17, 301-334.	0.8	68
45	Hemoptysis caused by erosion of thoracic aortic aneurysm. Cmaj, 2010, 182, E186-E186.	0.9	7
46	Predicting Postoperative FEV1 Using Spiral Computed Tomography. Academic Radiology, 2010, 17, 607-613.	1.3	3
47	Modulation of neutrophil apoptosis by murine pulmonary microvascular endothelial cell inducible nitric oxide synthase. Biochemical and Biophysical Research Communications, 2010, 401, 207-212.	1.0	7
48	Calpain-1 induces apoptosis in pulmonary microvascular endothelial cells under septic conditions. Microvascular Research, 2009, 78, 33-39.	1.1	41
49	Six-Minute Walk Test in Scleroderma-Associated Pulmonary Arterial Hypertension: Are We Counting What Counts?. Journal of Rheumatology, 2009, 36, 216-218.	1.0	12
50	Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: A qualitative systematic review. Canadian Journal of Cardiology, 2009, 25, e63-e68.	0.8	7
51	Human neutrophil-pulmonary microvascular endothelial cell interactions in vitro: Differential effects of nitric oxide vs. peroxynitrite. Microvascular Research, 2008, 76, 80-88.	1.1	22
52	The Clinical Significance of Exhaled Nitric Oxide in Asthma. Canadian Respiratory Journal, 2008, 15, 99-106.	0.8	23
53	Acute respiratory failure during pregnancy: a case of nitrofurantoin-induced pneumonitis. Cmaj, 2007, 176, 319-320.	0.9	12
54	Inducible NO synthase (iNOS) in human neutrophils but not pulmonary microvascular endothelial cells (PMVEC) mediates septic protein leak in vitro. Microvascular Research, 2007, 74, 23-31.	1.1	30

#	ARTICLE	IF	CITATIONS
55	Sitaxsentan Treatment for Patients With Pulmonary Arterial Hypertension Discontinuing Bosentan. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 63-69.	0.3	61
56	Albumin leak across human pulmonary microvascular vs. umbilical vein endothelial cells under septic conditions. <i>Microvascular Research</i> , 2006, 71, 40-47.	1.1	32
57	An Open-Label, Multicentre Pilot Study of Bosentan in Pulmonary Arterial Hypertension Related to Congenital Heart Disease. <i>Canadian Respiratory Journal</i> , 2006, 13, 415-420.	0.8	16
58	Thrombotic Arteriopathy and Anticoagulation in Pulmonary Hypertension. <i>Chest</i> , 2006, 130, 545-552.	0.4	121
59	EVOLUTION AND OUTCOMES OF A RAPID RESPONSE TEAM. <i>Chest</i> , 2006, 130, 218S.	0.4	68
60	Pulmonary oxidant stress in murine sepsis is due to inflammatory cell nitric oxide*. <i>Critical Care Medicine</i> , 2005, 33, 1333-1339.	0.4	88
61	The effects of nitric oxide in acute lung injury. <i>Vascular Pharmacology</i> , 2005, 43, 390-403.	1.0	85
62	Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. <i>Canadian Respiratory Journal</i> , 2005, 12, 303-315.	0.8	5
63	Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. <i>Canadian Journal of Cardiology</i> , 2005, 21, 909-14.	0.8	4
64	Pulmonary Neutrophil Infiltration in Murine Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 227-233.	2.5	151
65	Excess nitric oxide decreases cytochrome P-450 2J4 content and P-450-dependent arachidonic acid metabolism in lungs of rats with acute pneumonia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2004, 286, L1260-L1267.	1.3	14
66	Sildenafil for Pulmonary Arterial Hypertension. <i>Chest</i> , 2003, 123, 989-992.	0.4	25
67	Pulmonary cytochrome P-450 2J4 is reduced in a rat model of acute Pseudomonas pneumonia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2003, 285, L1099-L1105.	1.3	19
68	Role of Inducible Nitric Oxide Synthase in Pulmonary Microvascular Protein Leak in Murine Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1634-1639.	2.5	187
69	Effects of inhaled nitric oxide in a mouse model of sepsis-induced acute lung injury*. <i>Critical Care Medicine</i> , 2002, 30, 868-873.	0.4	66
70	Effects of Nebulized Diethylenetetraamine-NONOate in a Mouse Model of Acute Pseudomonas aeruginosa Pneumonia. <i>Chest</i> , 2002, 122, 2127-2136.	0.4	19
71	Functional Inhibition of Constitutive Nitric Oxide Synthase in a Rat Model of Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1426-1432.	2.5	83
72	Delayed rectifier potassium channels contribute to the depressed pulmonary artery contractility in pneumonia. <i>Journal of Applied Physiology</i> , 2002, 93, 957-965.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H2848-H2856.	1.5	110
74	Effect of Hemolyzed Plasma on the Batch Measurement of Nitrate by Nitric Oxide Chemiluminescence. <i>Clinical Chemistry</i> , 2001, 47, 1847-1851.	1.5	4
75	Noninvasive Measurement of Exhaled Nitric Oxide in a Spontaneously Breathing Mouse. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 1113-1116.	2.5	21
76	Effects of inhaled nitric oxide in a rat model of <i>Pseudomonas aeruginosa</i> pneumonia. <i>Critical Care Medicine</i> , 2000, 28, 2397-2405.	0.4	56
77	Randomized Trial of Prolonged Chloroquine Therapy in Advanced Pulmonary Sarcoidosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 192-197.	2.5	170
78	Contribution of Nitric Oxide Synthases 1, 2, and 3 to Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma. <i>Journal of Experimental Medicine</i> , 1999, 189, 1621-1630.	4.2	195
79	Painless Left Hemorrhagic Pleural Effusion. <i>Chest</i> , 1999, 116, 1478-1480.	0.4	27
80	Porcine endotoxemic shock is associated with increased expired nitric oxide. <i>Critical Care Medicine</i> , 1999, 27, 385-393.	0.4	290
81	Endogenous pulmonary nitric oxide in the regulation of airway microvascular leak. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L961-L968.	1.3	8
82	The Effects of Changes in Ventilation and Cardiac Output on Expired Nitric Oxide. <i>Chest</i> , 1997, 111, 1045-1049.	0.4	258
83	Contribution of type I NOS to expired gas NO and bronchial responsiveness in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1997, 273, L883-L888.	1.3	40
84	The Hypotensive Effect of L-Arginine Is Associated With Increased Expired Nitric Oxide in Humans. <i>Chest</i> , 1996, 109, 1550-1555.	0.4	61
85	Short-term Pulmonary Vasodilation With L-Arginine in Pulmonary Hypertension. <i>Circulation</i> , 1995, 92, 1539-1545.	1.6	149
86	The clinical consequences of a stiff left atrium. <i>American Heart Journal</i> , 1991, 122, 1184-1191.	1.2	71